Form 4: Savara Inc. Chief Medical Officer Acquires Shares and Options

Savara Inc.'s Chief Medical Officer, Raymond Dennis Pratt, acquired 80,000 shares of common stock and 280,000 stock options on December 12, 2024.

Summary

• Raymond Dennis Pratt, the Chief Medical Officer of Savara Inc., has reported acquiring 80,000 shares of common stock and 280,000 stock options.
• The 80,000 shares were granted as restricted stock units (RSUs) that will vest on December 12, 2026, contingent on continued service with the company.
• The 280,000 stock options have an exercise price of $3.35 and will vest in sixteen equal quarterly installments starting December 12, 2024, also subject to continued service.
• Following these transactions, Mr. Pratt now beneficially owns a total of 340,050 shares of common stock and 280,000 stock options.

Sentiment

Score: 7

Explanation: The document reflects a standard practice of equity compensation for a key executive, which is generally viewed positively as it aligns management's interests with shareholders. There are no indications of negative sentiment.

Positives

• The acquisition of shares and options by the Chief Medical Officer indicates confidence in the company's future.
• The vesting schedule of the RSUs and options incentivizes long-term commitment from the executive.

Risks

• The vesting of the shares and options is contingent on continued service, which introduces a risk of forfeiture if the executive leaves the company before the vesting dates.

Industry Context

This type of transaction is common in the biotech industry, where equity-based compensation is often used to attract and retain key executives. It aligns the interests of management with those of shareholders by incentivizing long-term value creation.

Comparison to Industry Standards

• Equity grants to executives are a standard practice in the biotechnology industry, often including a mix of stock options and restricted stock units.
• Vesting schedules, like the one described, are typical to ensure long-term commitment from key personnel.
• The specific terms of these grants, such as the exercise price and vesting period, are generally aligned with industry norms for companies of similar size and stage of development.

Stakeholder Impact

• The equity grants to the Chief Medical Officer may be viewed positively by shareholders as it aligns management's interests with the company's long-term success.
• Employees may see this as a positive sign of the company's commitment to its leadership team.

Key Dates

Keywords

Savara Inc, Raymond Dennis Pratt, Chief Medical Officer, stock options, restricted stock units, RSUs, insider trading, executive compensation, equity